Health Care/Hospital
Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successfu...
2025-11-11 09:00
956
GLAC Biotech Wins Double Honors at the iSEE Global Innovation Awards Lactobacillus plantarum PL-02 Sets a New Benchmark for Functional Probiotics
TAIPEI, Nov. 11, 2025 /PRNewswire/ -- GLAC Biotech, a leading innovator in probiotics and postbiotics research, proudly announces another milestone on the global stage. Its flagship strain,Lactobacillus plantarum PL-02, has been honored withtwo major awards at the 7th iSEE Global Innovation Award...
2025-11-11 09:00
1019
Vexev's VxWave System Successfully Meets Clinical Endpoints in Landmark Study Evaluating Robotic Ultrasound Scanning for Mapping Vascular Access at U.S. Renal Care Dialysis Clinics
* VxWave Ultrasound Imaging System demonstrated 94% scanning success rate and 100% data adequacy rate for vascular access creation strategies in CANSCAN trial * New insights into vascular anatomy made possible by standardized image acquisition and reporting * VxWave System has the potential t...
2025-11-11 05:32
1219
LiberNovo Launches Black Friday Savings: Redefine Your Workspace for Health
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- The season for serious deals has
arrived, and LiberNovo today launched its Black Friday & Cyber Monday (BFCM)
sale across across the U.S. and Canada—with limited-time discounts of up to 34%
on its flagship product,the LiberNovo Omni
2025-11-11 00:00
1639
TraceLink Customers Demonstrate Readiness as DSCSA Dispenser Deadline Arrives
TraceLink Continues to Set the Standard for United States Drug Supply Chain Security (DSCSA) Leadership, Proven by Real-World Success, Industry Adoption, and Superior Service BOSTON, Nov. 10, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestr...
2025-11-10 23:00
1097
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
* Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) * Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-...
2025-11-10 21:30
2096
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical data reveal potential applications in hemolyti...
2025-11-10 21:15
1091
Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"
* 70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical...
2025-11-10 21:00
1308
Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo
BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo duringNovember 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-...
2025-11-10 20:30
982
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study inChina for the treatment of moderate-to-severe atopi...
2025-11-10 20:06
1097
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)
SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences
2025-11-10 20:00
872
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the com...
2025-11-10 19:39
877
MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("M ediTrustHealth") signed a strategic cooperation agreement. The...
2025-11-10 14:18
1180
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycer...
2025-11-10 12:00
1363
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA), the Tengchong Science Forum Organizing Committee ...
2025-11-10 10:01
1366
ICP DAS-BMP Attends MOU Signing Ceremony to Mark a New Milestone in Medical-Grade TPU Materials
HSINCHU, Nov. 10, 2025 /PRNewswire/ -- ICP DAS-BMP participated in the Strategic Memorandum of Understanding (MOU) signing ceremony organized by Towards Buddha Co., Ltd. onOctober 28, where it showcased its R&D achievements and diverse applications in medical-grade TPU materials. Moving forward, ...
2025-11-10 08:45
1143
Xinhua Silk Road: E. China's Weihai City establishes 18 TCM health tourism demonstration bases
BEIJING, Nov. 8, 2025 /PRNewswire/ -- Weihai, a prefecture-level city in east China's Shandong Province, has seen the establishment of 18 traditional Chinese medicine (TCM) health tourism demonstration bases, including the Weihai Tianmu Hot Spring Resort, as the city has emphasized the deep integ...
2025-11-08 20:48
1804
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("...
2025-11-08 18:00
1290
inne Debuts at CIIE with Global Launch of Two New Products
SHANGHAI, Nov. 8, 2025 /PRNewswire/ -- The 8th China International Import Expo (CIIE) commenced onNov. 5 in Shanghai, China. The world's leading children's nutrition brand inne® was invited to participate, showcasing a range of its innovative achievements on this international stage and seizing t...
2025-11-08 11:23
1973
2025 Aurora Prize for Awakening Humanity Awarded to Dr. Jamal Eltaeb
Head of Al Nao Hospital in Sudan recognized for sustaining critical medical
care amid civil war
and saving hundreds of lives
NEW YORK, Nov. 8, 2025 /PRNewswire/ -- The Aurora Humanitarian Initiative
announced Thursday evening thatDr. Jamal Eltaeb
2025-11-08 00:03
725
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 286 media titles]
2025-12-10 16:00